EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Real‐World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual‐Center Cohort

Man Ting Xu iD, Alissa Wright, Allison Mah iD, Nancy Matic iD, Christopher Lowe iD, Casara Hong, Sara Belga iD, Wan-Yun Polinna Tsai iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-12 · 45 (12) · 815-824

DOI: 10.1002/phar.70086 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 24.12.2025. Verfasst von Man Ting Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Ribonucleosides, Benzimidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) is a major opportunistic infection in solid organ transplant (SOT) recipients. Although valganciclovir is first‐line for CMV treatment, its use may be limited by resistance and myelotoxicity. Letermovir (LET) and maribavir (MBV) are increasingly used as alternative therapies, though real‐world outcomes remain incompletely defined. This study evaluated real‐world outcomes of LET and MBV in SOT recipients for whom standard CMV therapy was inadequate or not feasible. Viral clearance, breakthrough infection, refractory infection, and resistance emergence were assessed.

Methods

We conducted a retrospective cohort analysis of adult SOT patients receiving LET (2018–2025) and/or MBV (2019–2025) at two transplant centers. Primary outcomes included CMV breakthrough (≥ 500 IU/mL) during LET prophylaxis and CMV clearance (< 200 IU/mL) at the end of MBV treatment. Secondary outcomes included resistant, refractory, and recurrent CMV infection within 3 months post‐therapy.

Results

Among 47 LET courses (41 patients), breakthrough CMV occurred in 14/32 (44%) secondary prophylaxis (SP) courses (median viral load [VL]: 1037 IU/mL, interquartile range [IQR] 673–3427) but in none of the 15 primary prophylaxis (PP) courses. No resistance to LET was detected during or after prophylaxis. MBV was administered in 21 courses (17 patients); MBV‐refractory/resistant (R/R) infection occurred in 8 courses (38%), and 11 (52%) courses achieved CMV clearance. Within 3 months post‐MBV, 14 (67%) courses had CMV VL ≥ 1000 IU/mL, and two (10%) courses experienced recurrence. MBV resistance emerged in 6/17 (35%) patients during or after treatment.

Conclusions

LET was effective for PP but associated with frequent breakthroughs in SP patients. MBV was limited by incomplete viral suppression and emergent resistance. These findings highlight the variable effectiveness of LET and MBV in clinical practice and support the need for further research to define optimal antiviral use in SP and refractory CMV treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsRibonucleosidesBenzimidazolesOrgan TransplantationQuinazolinesAcetatesHumansFemaleMaleRetrospective StudiesMiddle AgedDrug Resistance, ViralTransplant RecipientsTreatment OutcomeAdultCytomegalovirusAgedCohort StudiesDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

CMVletermovirmaribavirresistancetransplant

Substanzen

Antiviral AgentsletermovirmaribavirRibonucleosidesBenzimidazolesQuinazolinesAcetatesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • University of British Columbia, Vancouver, Canada.
  • Vancouver Costal Health, Vancouver, Canada.
  • Providence Health Care, Vancouver, Canada.
  • BC Transplant, Vancouver, Canada.

ORCID-Profile: Man Ting Xu, Allison Mah, Nancy Matic, Christopher Lowe, Sara Belga, Wan-Yun Polinna Tsai

Zitieren

APA

Xu, M. T., Wright, A., Mah, A., Matic, N., Lowe, C., Hong, C., Belga, S., & Tsai, W. P. (2025). Real‐World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual‐Center Cohort. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(12), 815-824. https://doi.org/10.1002/phar.70086

Vancouver

Xu MT, Wright A, Mah A, Matic N, Lowe C, Hong C, et al. Real‐World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual‐Center Cohort. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(12):815-824. doi:10.1002/phar.70086

BibTeX
@article{Xu2025,
  author = {Xu, Man Ting and Wright, Alissa and Mah, Allison and Matic, Nancy and Lowe, Christopher and Hong, Casara and Belga, Sara and Tsai, Wan-Yun Polinna},
  title = {Real‐World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual‐Center Cohort},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {12},
  pages = {815--824},
  doi = {10.1002/phar.70086}
}
Kostenlos starten →